CPRX
Income statement / Annual
Last year (2024), Catalyst Pharmaceuticals, Inc.'s total revenue was $491.73 M,
an increase of 23.49% from the previous year.
In 2024, Catalyst Pharmaceuticals, Inc.'s net income was $163.89 M.
See Catalyst Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$491.73 M |
$398.20 M |
$214.20 M |
$140.83 M |
$119.07 M |
$102.31 M |
$500,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$68.85 M
|
$84.53 M
|
$34.39 M
|
$21.88 M
|
$17.04 M
|
$14.76 M
|
$19.92 M
|
$45,689.00
|
$43,406.00
|
$34,468.00
|
| Gross Profit |
$422.89 M
|
$313.67 M
|
$179.81 M
|
$118.95 M
|
$102.03 M
|
$87.55 M
|
-$19.42 M
|
-$45,689.00
|
-$43,406.00
|
-$34,468.00
|
| Gross Profit Ratio |
0.86
|
0.79
|
0.84
|
0.85
|
0.86
|
0.86
|
-38.84
|
0
|
0
|
0
|
| Research and Development Expenses |
$12.65 M
|
$93.15 M
|
$19.79 M
|
$16.94 M
|
$16.50 M
|
$18.84 M
|
$19.92 M
|
$11.38 M
|
$11.37 M
|
$11.80 M
|
| General & Administrative Expenses |
$66.40 M
|
$47.02 M
|
$28.71 M
|
$23.48 M
|
$20.67 M
|
$33.58 M
|
$15.88 M
|
$7.30 M
|
$7.91 M
|
$8.60 M
|
| Selling & Marketing Expenses |
$111.34 M
|
$86.69 M
|
$29.47 M
|
$26.15 M
|
$23.57 M
|
$3.30 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$177.74 M
|
$133.71 M
|
$58.18 M
|
$49.63 M
|
$44.23 M
|
$36.88 M
|
$15.88 M
|
$7.30 M
|
$7.91 M
|
$8.60 M
|
| Other Expenses |
$37.38 M
|
$0.00
|
$2.88 M
|
$282,000.00
|
$586,897.00
|
$1.59 M
|
$1.29 M
|
$454,163.00
|
$321,612.00
|
$100,389.00
|
| Operating Expenses |
$227.77 M
|
$259.43 M
|
$77.97 M
|
$66.56 M
|
$60.73 M
|
$55.72 M
|
$35.80 M
|
$18.68 M
|
$19.28 M
|
$20.40 M
|
| Cost And Expenses |
$296.61 M
|
$311.39 M
|
$112.37 M
|
$88.45 M
|
$77.77 M
|
$70.48 M
|
$35.80 M
|
$18.68 M
|
$19.28 M
|
$20.40 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$282,000.00
|
$587,000.00
|
$1.59 M
|
$1.29 M
|
$454,163.00
|
$321,612.00
|
$100,389.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.29 M
|
$454,163.00
|
$321,612.00
|
$100,389.00
|
| Depreciation & Amortization |
$0.00
|
$32.88 M
|
$1.49 M
|
$484,000.00
|
$885,317.00
|
$297,726.00
|
$37,978.00
|
$45,689.00
|
$43,406.00
|
$34,468.00
|
| EBITDA |
$195.12 M |
$119.69 M |
$101.84 M |
$52.39 M |
$41.30 M |
$31.82 M |
-$35.26 M |
-$18.49 M |
-$18.03 M |
-$20.46 M |
| EBITDA Ratio |
0.4
|
0.3
|
0.48
|
0.37
|
0.35
|
0.31
|
-70.59
|
0
|
0
|
0
|
| Operating Income Ratio |
0.4
|
0.22
|
0.48
|
0.37
|
0.35
|
0.31
|
-70.59
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$21.14 M
|
$7.70 M
|
$2.88 M
|
$282,000.00
|
$586,897.00
|
$1.59 M
|
$1.29 M
|
$267,259.00
|
$1.21 M
|
$165,394.00
|
| Income Before Tax |
$216.26 M
|
$94.51 M
|
$104.72 M
|
$52.67 M
|
$41.89 M
|
$33.41 M
|
-$34.00 M
|
-$18.41 M
|
-$18.07 M
|
-$20.23 M
|
| Income Before Tax Ratio |
0.44
|
0.24
|
0.49
|
0.37
|
0.35
|
0.33
|
-68.01
|
0
|
0
|
0
|
| Income Tax Expense |
$52.37 M
|
$23.10 M
|
$21.64 M
|
$13.19 M
|
-$33.09 M
|
$1.53 M
|
$2.58 M
|
$141,215.00
|
-$929,543.00
|
-$99,473.00
|
| Net Income |
$163.89 M
|
$71.41 M
|
$83.08 M
|
$39.48 M
|
$74.98 M
|
$31.88 M
|
-$34.00 M
|
-$18.41 M
|
-$18.07 M
|
-$20.23 M
|
| Net Income Ratio |
0.33
|
0.18
|
0.39
|
0.28
|
0.63
|
0.31
|
-68.01
|
0
|
0
|
0
|
| EPS |
1.38 |
0.67 |
0.8 |
0.38 |
0.72 |
0.31 |
-0.33 |
-0.21 |
-0.22 |
-0.25 |
| EPS Diluted |
1.31 |
0.63 |
0.75 |
0.37 |
0.71 |
0.3 |
-0.33 |
-0.21 |
-0.22 |
-0.25 |
| Weighted Average Shares Out |
$118.46 M
|
$106.28 M
|
$103.37 M
|
$103.38 M
|
$103.51 M
|
$102.94 M
|
$102.63 M
|
$85.80 M
|
$82.88 M
|
$80.86 M
|
| Weighted Average Shares Out Diluted |
$124.94 M
|
$113.75 M
|
$111.38 M
|
$107.80 M
|
$106.24 M
|
$106.02 M
|
$102.63 M
|
$85.80 M
|
$82.88 M
|
$80.86 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
